US FDA Issues Warning Letter to Aurobindo Pharma's Eugia Pharma Unit

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma. This action pertains to a formulation manufacturing facility located near Hyderabad.

What Happened

The warning letter follows an inspection by the U.S. FDA that resulted in four observations in February and an Official Action Indicated (OAI) status in May. Eugia Pharma Specialities received the formal warning letter after this designation. Aurobindo Pharma announced the development on Friday, August 14, 2026.

Key Facts

• The U.S. Food and Drug Administration (FDA) issued a warning letter to Eugia Pharma Specialities.
• Eugia Pharma Specialities is a subsidiary of Aurobindo Pharma.
• The facility in question is a formulation manufacturing unit near Hyderabad.
• The warning letter followed an inspection that resulted in four observations in February and an Official Action Indicated (OAI) status in May.
• Aurobindo Pharma stated that the warning letter is not expected to impact existing supplies to the U.S. markets.
• The affected facility contributes approximately 2% to Aurobindo Pharma’s overall group revenue.
• Parent company revenue for the quarter ended June was ₹9,150 crore, and for FY26 it was ₹33,653 crore.
• Aurobindo Pharma announced the incorporation of a new subsidiary, Auropharm Overseas, on August 13 for manufacturing and marketing operations.
• The U.S. FDA categorizes facilities as Official Action Indicated (OAI), No Action Indicated (NAI), or Voluntary Action Indicated (VAI).

Background

Following an inspection, the U.S. FDA categorizes manufacturing facilities into three statuses: Official Action Indicated (OAI), which recommends regulatory or administrative actions; No Action Indicated (NAI), meaning no objectionable practices were found; and Voluntary Action Indicated (VAI), where objectionable practices were found but do not necessitate administrative or regulatory action.

Aurobindo Pharma also announced on August 13 the establishment of a new, wholly owned subsidiary named Auropharm Overseas in India. This new entity is intended for both domestic and international manufacturing and marketing activities.